Exonhit Therapeutics

ExonHit Therapeutics SA engages in the development of molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. It involves in the exploitation of alternative RNA splicing, the process by which a single gene can produce several proteins. The company offers AclarusDx, a blood-based test to select or stratify patients suffering from Alzheimer's disease in clinical research. Its products also include EHT Dx14, a breast cancer diagnostic biomarker; EHT Dx11, blood-based diagnostic test for breast cancer; and EHT Dx12 to identify specific biomarkers for colon cancer, as well as EHT Dx13, a blood-based diagnostic test for prostate cancer. The company's therapeutic product compounds include EHT 0202, a GABAA receptor modulator and a PDE4 inhibitor for the treatment of Alzheimer's disease; EHT/AGN 0001 for pain indications; EHT/AGN 0002 to treat pain and neurodegeneration, as well as for applications in the field of ophthalmology; and EHT/AGN 0003 for opthalmology and neurodegenerative indications. In addition, its preclinical portfolio includes EHT 101 and EHt 107 programs for oncology. The company has strategic collaborations with bioMérieux to develop customized SpliceArray biochips to detect cancer markers in blood samples; and Allergan to discover drugs in the fields of ophthalmology, pain, and neurodegenerative diseases. ExonHit Therapeutics was founded in 1997 and is headquartered in Paris, France. Key Numbers Market cap 45.6M EUR Sales 8.5M EUR Quarterly revenue growth 22% ( this is very important as from here it accellerates, actually revenues were increasing from the start but with latest collaboration with Allergan Inc. and Bristol Myers Squibb revenues will increase even faster) EPS, Income, EBITDA all negative as company till lately was in development stage, but now there is a real product in Alzheimer's diagnostics, potential to so big that nobody cares about balance sheet here) Cash 26M EUR LT Debt 7M EUR (very nicely managed when it comes to debt, even from quantitative view there is risk for the stock) Assets 45M EUR Liabilities 17.5M EUR (here also no problem as you assets are much higher than liabilities, besides 50% of market cap is cash, it's rare as diamonds you will find today walking on the street, ExonHit is not only in medical diagnostics, they have some therapeutics too but in early phases) Employees 66 from them 46 are scientists, 5 executives running company are Phd. , M.D& MBA graduates Shares Outstanding 33,300,000 Ffree Float 30,600,000 (I just imagine somebody will start increasing position here, it will be very nice to see it coming) Major Investors: Oxford Bioscience Partners Group 7.8% Groupe PRO BTP 3% Other institutions 5.3% Finally